Brazil Tuesday suspended its deal with Bharat Biotech for 20 million Covaxin doses amid an ongoing investigation into alleged irregularities & corruption. ThePrint gives you the details.
Interim results from the phase 3 trial indicate that Covaxin has 78% efficacy against symptomatic disease & 100% efficacy against severe Covid, including hospitalisation, NIH said.
Subject Expert Committee, which advises DCGI on approvals for new drugs & vaccines. has not yet discussed changing the status of Covaxin from emergency use to full licensure.
Bharat Biotech submitted phase 3 trial data of Covaxin to the Drug Controller General of India. The data is crucial to ascertaining the efficacy of a vaccine.
A pre-submission meeting with WHO will take June 23 during which the vaccine maker will have an opportunity to submit a summary on the overall quality of the jab.
Bharat Biotech said reasons such as low procurement volumes, high distribution costs and retail margins among others contribute to the higher pricing of Covaxin.
The Drugs Controller General of India had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on 12 May.
Many 'independent' reports, intended to shape policies, are sponsored by industry groups or entities with deep pockets and vested interests. This process must become transparent.
While the move could free up grid capacity struggling to keep up with rapid renewable rollout, it would be a major setback for green ambitions. India aims to double clean power capacity to 500 gigawatts by the end of the decade.
Agreement signed during 17th Joint Working Group (JWG) on defence cooperation. Defence Secretary Rajesh Kumar Singh met Director General in Israeli Ministry of Defence Amir Baram Tuesday.
This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.
COMMENTS